Skip to main content

Vertex Pharmaceuticals Inc

VRTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000875320

No open-market purchases or sales by Vertex Pharmaceuticals Inc insiders were filed in the last 90 days; 1,762 institutions reported holding it in 13F filings for Q2 2026, worth $119.7B in total; no superinvestor holds it.

13F holders, Q4 2022

Institutional positions in Vertex Pharmaceuticals Inc as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
1,224
+121 vs. Q3 2022
Shares held
237.1M
+549.4K (+0.2%) vs. Q3 2022
Total value
$68.3B
−$59.7M (−0.1%) vs. Q3 2022
New holders
185
438 more added
Sold out
64
440 more reduced

24 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting VRTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2022: 1,224 institutions
Q1 2021: 1,000 institutionsQ2 2021: 979 institutionsQ3 2021: 936 institutionsQ4 2021: 1,034 institutionsQ1 2022: 1,072 institutionsQ2 2022: 1,109 institutionsQ3 2022: 1,127 institutionsQ4 2022: 1,224 institutionsQ1 2023: 1,212 institutionsQ2 2023: 1,287 institutionsQ3 2023: 1,280 institutionsQ4 2023: 1,442 institutionsQ1 2024: 1,497 institutionsQ2 2024: 1,551 institutionsQ3 2024: 1,551 institutionsQ4 2024: 1,563 institutionsQ1 2025: 1,617 institutionsQ2 2025: 1,563 institutionsQ3 2025: 1,523 institutionsQ4 2025: 1,671 institutionsQ1 2026: 1,698 institutionsQ2 2026: 1,762 institutions
Value heldQ4 2022: $68.3B
Q1 2021: $50.6BQ2 2021: $46.8BQ3 2021: $41.9BQ4 2021: $50.4BQ1 2022: $60.9BQ2 2022: $66.1BQ3 2022: $68.5BQ4 2022: $68.3BQ1 2023: $75.0BQ2 2023: $83.3BQ3 2023: $81.9BQ4 2023: $95.7BQ1 2024: $98.0BQ2 2024: $109.9BQ3 2024: $109.1BQ4 2024: $95.2BQ1 2025: $116.3BQ2 2025: $107.2BQ3 2025: $90.8BQ4 2025: $109.5BQ1 2026: $106.1BQ2 2026: $119.7B
Institutions holding VRTX and their total value by quarter
QuarterHoldersValue
Q2 20261,762$119.7B
Q1 20261,698$106.1B
Q4 20251,671$109.5B
Q3 20251,523$90.8B
Q2 20251,563$107.2B
Q1 20251,617$116.3B
Q4 20241,563$95.2B
Q3 20241,551$109.1B
Q2 20241,551$109.9B
Q1 20241,497$98.0B
Q4 20231,442$95.7B
Q3 20231,280$81.9B
Q2 20231,287$83.3B
Q1 20231,212$75.0B
Q4 20221,224$68.3B
Q3 20221,127$68.5B
Q2 20221,109$66.1B
Q1 20221,072$60.9B
Q4 20211,034$50.4B
Q3 2021936$41.9B
Q2 2021979$46.8B
Q1 20211,000$50.6B

Institutions, Q4 2022

Shares, value and share of portfolio for each institution holding Vertex Pharmaceuticals Inc; share changes are against Q3 2022.

Institutions holding VRTX in Q4 2022
InstitutionSharesValue% of portfolioChange in sharesAction
55I, LLC––––Not filed
Wipfli Financial Advisors LLC,––––Not filed
FourThought Financial, LLC––––Not filed
Lloyd Park, LLC––––Not filed
17 Capital Partners, LLC––––Not filed
Jefferies Group LLC––––Not filed
H. L. Ormond & Company, LLC––––Not filed
American Portfolios Advisors––––Not filed
Roberts Capital Advisors, LLC––––Not filed
Spectrum Management Group, LLC––––Not filed
Covington Capital Management––––Not filed
Danda Trouve Investment Management, Inc.––––Not filed